New research from Emory University is providing a more precise prediction of COVID-19 severity that can be found by looking at autoantibodies in the nasal cavity, leading to more personalized treatment plans.

New research from Emory University reveals that nasal autoantibodies in COVID-19 patients may help predict disease severity, with potential implications for treatment. COVID-19 symptoms vary widely, from mild to severe.

It provides a more precise prediction than currently available of how serious the case is by focusing on autoantibodies in the nasal cavity.

A wide variety of COVID-19 symptoms exist, ranging from mild to severe, and while current strains of the virus generally cause milder symptoms, those with co-morbidities are still at an exponentially greater risk of severe disease.